231. Demand Policy Instruments for R Procurement, Technical Standards and The Case of Indian Vaccines
- Author:
- Smita Srinivas
- Publication Date:
- 12-2004
- Content Type:
- Working Paper
- Institution:
- Belfer Center for Science and International Affairs, Harvard University
- Abstract:
- Vaccines represent a nearly $8 billion global industry today , which is projected to grow to $10 billion in 2010 (PhRMA, 2001). In 2001, worldwide spending on R for “biologicals,” of which vaccines are the largest segment, was $1.1 billion (about 4% of total private pharmaceutical R) (PhRMA, 2001). Although vaccines com p rise only 2% of the global pharmaceutical market, it is indispensable for public health immunization the world over. Yet, at the same time, the number of private vaccine suppliers in advanced industrialised countries is shrinking (in the US alone, there were over twenty vaccine suppliers until the 1970s and now approximately five exist); firm s in developing countries must pick up some of this slack, especially for vaccines that are especially important for diseases prevalent in developing countries.
- Topic:
- Energy Policy, Human Welfare, Industrial Policy, and Science and Technology